Bringing you live news and features since 2006 

Solactive launches Pharma & Biotech Opportunity Index


Solactive AG has launched the Solactive Pharma & Biotech Opportunity Index, which will be used as underlying by Société Générale Corporate & Investment Banking (SG CIB) for an Open End Certificate targeting IFAs as well as clients in retail and private banking based both in Germany and Austria.

With existing costs and in-house resources needed to take a new drug concept and turn it into an approved, effective treatment, M&A has been common practice in the pharmaceutical industry for decades. As the competition for tomorrow's blockbuster drugs has intensified in an era of historically low interest rates, many big drug makers have been looking at buying smaller, biotech companies to refill their R&D pipeline – AbbVie’s acquisition of Pharmacyclics for USD 21 billion is the latest example of that trend. Since the start of last year, deals have indeed been mostly smaller and more targeted than in the past; but as they are abundant they have reached a record of around USD 470 billion over that period and many more are expected to follow.
Steffen Scheuble, CEO, Solactive, says: “Being close to the market, following the latest trends and launching first of their kinds indices is key to an Index Provider. The Solactive Pharma & Biotech Opportunity Index is a great example of an innovative idea with a huge potential – tracking stocks in the growing pharma & biotech industry whose price would benefit from the premium paid if they do get acquired.”
Peter Bösenberg, Director – Head of Public Distribution Germany & Austria, SG CIB, says: “Through the new Open End Certificate on the Pharma & Biotech Opportunity-Index, Investors have an interesting opportunity to benefit from the increasing M&A Activity in terms of the consolidation of the Pharma & Biotech Industry.”

Latest News

Figment Europe, a provider of institutional staking infrastructure, writes that it is solidifying its presence in the heart of Europe’s..
Saving and investing app, Moneybox, has doubled the number of ETFs available on the platform, in the light of ‘growing..
Global X ETFs has announced the appointment of Ryan O'Connor as its Chief Executive Officer effective as of April 8, 2024. ..
Value-driven structured credit investing firm, Angel Oak Capital Advisors, LLC, has announced the completed conversions of two of its mutual..

Related Articles

Ryan McCormack, Invesco
This year sees the 25th anniversary of Invesco’s QQQ, the USD240 billion ETF – the fifth largest ETF in the...
The European ETF market achieved a record 28 per cent growth – reaching over USD1.8 trillion assets under management (AUM)...
Sal Esposito, Zacks Investment Management
Zacks Investment Management started doing investment research in 1978 and in 1992 started its investment management arm, initially with SMAs...
Jeremy Senderowicz, Vedder Price
Jeremy Senderowicz, a member of the Investment Services Group at law firm Vedder Price, has witnessed a steady upswing in...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by